BioSpace News Archive

Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.

Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 of units at an issue price of $0.075 per Unit.

Iovance Biotherapeutics, Inc. announced a clinical program update for LN-145 TIL therapy in non-small lung cancer.

Novocure announced that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused both on development of inflammation and immunology biological products and provision of boutique CDMO services, announced that the Company will host an analyst and investors webinar event on January 9, 2024.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. and a clinical stage biotechnology company developing ultra-high concentration nitric oxide as an immunotherapeutic for solid tumors, announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose UNO by the Safety Review Committee with no reported dose limiting toxicities.

There’s a rhythm to developing life. Growing from a tiny cell cluster into an adult organism takes precise timing and control.

NKGen Biotech Inc. announced that it has received a No Objection Letter from Health Canada for its Clinical Trial Application for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer cell therapy for treatment of patients with moderate Alzheimer’s Disease.

Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, announced that the Company’s management team will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 7 – 11, 2024.

Visiox Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market.